The economic impact of Staphylococcus aureus infection in New York City hospitals.
| Autor: | Rubin, Robert J., Harrington, Catherine A., Poon, Anna, Dietrich, Kimberly, Greene, Jeremy A., Moiduddin, Adil, Rubin, R J, Harrington, C A, Poon, A, Dietrich, K, Greene, J A, Moiduddin, A |
|---|---|
| Předmět: |
STAPHYLOCOCCUS aureus infections
NOSOCOMIAL infections VANCOMYCIN resistance ENTEROCOCCUS MEDICAL care cost statistics CROSS infection LENGTH of stay in hospitals HOSPITAL costs METHICILLIN resistance STAPHYLOCOCCAL diseases STAPHYLOCOCCUS aureus URBAN hospitals COST analysis COMMUNITY-acquired infections DISCHARGE planning DISEASE incidence |
| Zdroj: | Emerging Infectious Diseases; Jan/Feb99, Vol. 5 Issue 1, p9-17, 9p, 1 Graph |
| Abstrakt: | We modeled estimates of the incidence, deaths, and direct medical costs of Staphylococcus aureus infections in hospitalized patients in the New York City metropolitan area in 1995 by using hospital discharge data collected by the New York State Department of Health and standard sources for the costs of health care. We also examined the relative impact of methicillin-resistant versus -sensitive strains of S. aureus and of community-acquired versus nosocomial infections. S. aureus-associated hospitalizations resulted in approximately twice the length of stay, deaths, and medical costs of typical hospitalizations; methicillin-resistant and -sensitive infections had similar direct medical costs, but resistant infections caused more deaths (21% versus 8%). Community-acquired and nosocomial infections had similar death rates, but community-acquired infections appeared to have increased direct medical costs per patient ($35,300 versus $28,800). The results of our study indicate that reducing the incidence of methicillin-resistant and -sensitive nosocomial infections would reduce the societal costs of S. aureus infection. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|